

17 December 2025

Treatment of Breast Cancer

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	49
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	1
1.4 Fulvestrant (fulvestrant or Faslodex)	26
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	37
1.7 Ribociclib (Kisqali)	27
1.8 Capivasertib (Truqap)	4
1.9 Talazoparib (Talzenna)	1
1.10 Olaparib (Lynparza)	21

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	49
2.2 Ribociclib (Kisqali)	27
2.3 Olaparib (Lynparza)	0

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

This information is not available.

17 December 2025

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	NA
3.2 Ribociclib (Kisqali)	NA

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	5
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	<5
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<5

Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025?

Type of breast cancer	Number patients treated
5.1 Olaparib - All types of breast cancer	<5
5.2 Olaparib - Locally advanced or metastatic breast cancer	Not Available
5.3 Talazoparib – All types of breast cancer	<5

Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	<5
6.2 Pertuzumab with Trastuzumab (Phesgo)	21
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zerceptac, trastuzumab)	33
6.4 Trastuzumab Deruxtecan (EnHertu)	13

17 December 2025

6.5 Trastuzumab Emtansine (Kadcyla)	10
6.6 Tucatinib (Tukysa)	<5
6.7 Neratinib (Nerlynx)	<5

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	22
7.2 Trastuzumab Deruxtecan (EnHertu)	13

Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

This information is not available.

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	NA
8.2 Pertuzumab with Trastuzumab (Phesgo)	NA
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	NA
8.4 Trastuzumab Emtansine (Kadcyla)	NA

17 December 2025

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

This information is not available.

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)	NA	NA	NA
9.2 Pertuzumab with Trastuzumab (Phesgo)	NA	NA	NA
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	NA	NA	NA
9.4 Trastuzumab Emtansine (Kadcyla)	NA	NA	NA

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

This information is not available.

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	NA
10.2 HER2-low Breast Cancer	NA

Q11. How many patients were treated for the following indications for metastatic HER2+ve breast cancer by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available?

This information is not available.

Name of medicine	Line of Therapy (indication)	Number patients treated
11.1 Trastuzumab Deruxtecan (Enhertu)	Following one or more prior anti-HER2-based regimens	NA

17 December 2025

11.2 Trastuzumab Deruxtecan (Enhertu)	Following one prior anti HER2-based regimen	NA
11.3 Trastuzumab Emtansine (Kadcyla)	Following one or more prior anti-HER2-based regimens	NA
11.4 Trastuzumab Emtansine (Kadcyla)	Following one prior anti HER2-based regimen	NA
11.5 Trastuzumab	Following one or more prior anti-HER2-based regimens	NA
11.6 Trastuzumab	Following one prior anti HER2-based regimen	NA